checkAd

     336  0 Kommentare OSE Immunotherapeutics Will Participate in HealthTech Investor Days (HTID) - Seite 2

    Click and follow us on Twitter and Linkedln

    Forward-looking statements

    This press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics’ management in light of its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate.

    These forward-looking statements include statements typically using conditional and containing verbs such as “expect”, “anticipate”, “believe”, “target”, “plan”, or “estimate”, their declensions and conjugations and words of similar import. Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics’ shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance. This press release includes only summary information and should be read with the OSE Immunotherapeutics Reference Document filed with the AMF on 26 April 2019, including the annual financial report for the fiscal year 2018, available on the OSE Immunotherapeutics’ website.

    Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements.

    Seite 2 von 2


    Diskutieren Sie über die enthaltenen Werte


    Business Wire (engl.)
    0 Follower
    Autor folgen

    OSE Immunotherapeutics Will Participate in HealthTech Investor Days (HTID) - Seite 2 Regulatory News: OSE Immunotherapeutics (Paris:OSE) (ISIN: FR0012127173; Mnémo: OSE) will participate in the first HeathTech Investor Days business event, hosted by France Biotech on June 24th & 25th in Paris. This first ever European event will …